- Capital Cube•9 days agoIntellipharmaceutics International, Inc. :I-CA: Earnings Analysis: Q4, 2016 By the Numbers : February 15, 2017
Categories: Yahoo Finance Get free summary analysis Intellipharmaceutics International, Inc. reports financial results for the quarter ended November 30, 2016. We analyze the earnings along side the following peers of Intellipharmaceutics International, Inc. – Theratechnologies Inc. (TH-CA) that have also reported for this period. Highlights Summary numbers: Revenues of CAD 0.75 million, Net Earnings of CAD -5.19 million. ... Read more (Read more...)
- GlobeNewswire•14 days ago
TORONTO, Feb. 10, 2017-- Intellipharmaceutics International Inc., a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release ...
- GlobeNewswire•21 days agoIntellipharmaceutics Announces FDA Acceptance for Filing of NDA for Rexista™ (oxycodone hydrochloride extended release), an Abuse Deterrent Opioid Analgesic for the Treatment of Moderate to Severe Pain
TORONTO, Feb. 02, 2017-- Intellipharmaceutics International Inc., a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release ...
I.TO : Summary for INTELLIPHARMACEUTICS INTERNATIO - Yahoo Finance
IntelliPharmaCeutics International Inc. (I.TO)
Toronto - Toronto Delayed Price. Currency in CAD
Add to watchlist
|Day's Range||2.78 - 3.06|
|52 Week Range||1.78 - 4.50|
|PE Ratio (TTM)||-7.39|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|